MDB Capital Holdings
  • About
    • About Us
    • Team
    • Holistic Model
  • Criteria
  • Process
  • Community
  • Companies
  • Investors
  • Submit Your Big Idea
Select Page

Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

by Tony Dammicci | Mar 15, 2023 | Press Releases

Paris and  Red Bank, N.J. March  13, 2023 Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under...

Recent Posts

  • MDB Capital Holdings Announces Closing of Public Offering of $20 Million
  • Video: MDB Capital Holdings Offering Presentation (Tahoe)
  • Video: MDB Capital Holdings Offering Presentation
  • Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
  • MDB Capital Holdings Announces Third MDB-Launched Company to Achieve FDA Approval

Recent Comments

    Archives

    • September 2023
    • August 2023
    • March 2023
    • November 2022
    • October 2022
    • August 2022
    • July 2022
    • June 2022

    Categories

    • Press Releases
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    AboutCriteriaProcessCommunityCompaniesTeamInvestorsContact

    Governance   Terms of Use   Business Continuity
    © 2023 MDB Capital Holdings